相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
D. L. Richardson et al.
GYNECOLOGIC ONCOLOGY (2010)
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
Rebecca L. Stone et al.
LANCET ONCOLOGY (2010)
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
P. Bono et al.
ANNALS OF ONCOLOGY (2009)
Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
Sanjaykumar Hapani et al.
LANCET ONCOLOGY (2009)
Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers
Robert Morris et al.
GYNECOLOGIC ONCOLOGY (2008)
Weekly topotecan for recurrent platinum resistant ovarian cancer
Fadi Abushahin et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics
Susan C. Modesitt et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer
Tamar Safra et al.
GYNECOLOGIC ONCOLOGY (2007)
Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer
SM Bhoola et al.
GYNECOLOGIC ONCOLOGY (2004)
Dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients
HD Homesley et al.
GYNECOLOGIC ONCOLOGY (2001)
分享论文
